{"id":53353,"date":"2023-09-20T09:45:18","date_gmt":"2023-09-20T09:45:18","guid":{"rendered":"https:\/\/medsname.com\/keytruda\/"},"modified":"2026-04-30T10:25:12","modified_gmt":"2026-04-30T10:25:12","slug":"keytruda","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/keytruda\/","title":{"rendered":"Keytruda"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 R\u0103spuns rapid \u2014 Ce este Keytruda?<\/h3>\n<p style=\"margin:0;\"><strong>Keytruda<\/strong> este un <strong>perfuzie intravenoas\u0103<\/strong> de la Merck (MSD) care con\u021bine <strong>pembrolizumab 100 mg\/4 mL<\/strong> \u2014 un anticorp monoclonal umanizat \u0219i <strong>inhibitor al punctului de control imun PD-1<\/strong>. Pembrolizumab deblocheaz\u0103 recunoa\u0219terea celulelor canceroase de c\u0103tre sistemul imun. Aprobat pentru <strong>multiple tipuri de cancer<\/strong>: melanom avansat, cancer pulmonar non-microcit (NSCLC), carcinom scuamos de cap \u0219i g\u00e2t, limfom Hodgkin clasic, carcinom urotelial, cancere MSI-H\/dMMR (orice tip de tumoare), cancer gastric, cancer esofagian, cancer cervical, carcinom hepatocelular, carcinom renal, cancer endometrial, cancer de s\u00e2n triplu negativ \u0219i alte c\u00e2teva. Doz\u0103 standard pentru adul\u021bi: <strong>200 mg IV la fiecare 3 s\u0103pt\u0103m\u00e2ni<\/strong> SAU <strong>400 mg IV la fiecare 6 s\u0103pt\u0103m\u00e2ni<\/strong>, perfuzat \u00een 30 de minute. <strong>Administrat exclusiv \u00eentr-un spital sau centru de zi de oncologie de personal calificat \u2014 nu pentru auto-administrare.<\/strong> Riscuri principale: <strong>evenimente adverse legate de sistemul imunitar (irAEs)<\/strong> \u2014 pot afecta orice sistem de organe (pneumonit\u0103, colit\u0103, hepatit\u0103, endocrinopatii, reac\u021bii cutanate, nefrit\u0103, neuropatie) \u0219i pot necesita corticosteroizi sistemici \u0219i \u00eentrerupere permanent\u0103.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:0 0 24px 0;border-radius:4px;font-size:14px;\"><strong>\u26a0 Supraveghere specializat\u0103 necesar\u0103.<\/strong> Medicamentele pentru cancer trebuie prescrise de un oncolog tratant, cu un diagnostic confirmat, stadializare ini\u021bial\u0103 \u0219i un plan de tratament definit. Nu \u00eencepe\u021bi, nu opri\u021bi, nu modifica\u021bi doza \u0219i nu utiliza\u021bi medicamente pentru cancer \u00een afara unui plan de \u00eengrijire condus de oncologie. Majoritatea medicamentelor pentru cancer necesit\u0103 monitorizare regulat\u0103 prin analize de s\u00e2nge (hemoleucogram\u0103, teste hepatice, func\u021bie renal\u0103), sunt absolut contraindicate \u00een sarcin\u0103 \u0219i au interac\u021biuni medicamentoase semnificative.<\/div>\n<div style=\"background:#f4f8fb;border:1px solid #d6e4ec;padding:12px 18px;margin:14px 0;border-radius:4px;font-size:14px;color:#3a5160;text-align:center;\">\n<strong>\ud83d\udd12 Checkout criptat<\/strong> \u00b7 <strong>\ud83d\udcb3 Procesor verificat<\/strong> \u00b7 <strong>\ud83d\ude9a Livrare worldwide<\/strong> \u00b7 <strong>\u2b50 4,9\/5 de la peste 1.400 de clien\u021bi<\/strong>\n<\/div>\n<h2 class=\"wp-block-heading\">Ce este Keytruda?<\/h2>\n<p>Keytruda (<strong>pembrolizumab<\/strong>) este un anticorp monoclonal IgG4 umanizat de la Merck (MSD) care \u021binte\u0219te <strong>proteina 1 de moarte celular\u0103 programat\u0103 (PD-1)<\/strong> receptor pe celulele T. Prin blocarea PD-1, pembrolizumab elibereaz\u0103 fr\u00e2nele imunitare pe care celulele canceroase le exploateaz\u0103 pentru a evita distrugerea imun\u0103. Aprobat de FDA \u00een 2014, Keytruda este acum autorizat pentru mai multe indica\u021bii oncologice dec\u00e2t orice alt\u0103 imunoterapie \u0219i a transformat tratamentul pentru melanom avansat, NSCLC avansat \u0219i multe alte tipuri de tumori.<\/p>\n<p>Pembrolizumab este furnizat sub form\u0103 de <strong>solu\u021bie concentrat\u0103 pentru perfuzie (flacon de 100 mg\/4 mL)<\/strong> care este diluat\u0103 \u00een ser fiziologic sau dextroz\u0103 5% \u0219i administrat\u0103 ca perfuzie intravenoas\u0103 lent\u0103 pe durata a 30 de minute \u00eentr-un spital sau unitate de zi oncologic\u0103. Nu este <strong>prime\u0219te,<\/strong> disponibil sub form\u0103 oral\u0103 \u0219i nu poate fi autoadministrat.<\/p>\n<h2 class=\"wp-block-heading\">Cum func\u021bioneaz\u0103 Keytruda?<\/h2>\n<p>Celulele canceroase exprim\u0103 frecvent <strong>PD-L1<\/strong> pe suprafa\u021ba lor. C\u00e2nd PD-L1 se leag\u0103 de <strong>PD-1<\/strong> receptorul de pe un celul\u0103 T infiltrat\u0103 \u00een tumoare semnalizeaz\u0103 celulei T s\u0103 se retrag\u0103 \u2014 dezactiv\u00e2nd efectiv r\u0103spunsul imun \u00eempotriva tumorii. Pembrolizumab este conceput pentru a bloca aceast\u0103 interac\u021biune PD-1 \/ PD-L1:<\/p>\n<ul>\n<li><strong>Elibereaz\u0103 fr\u00e2na imun\u0103<\/strong> \u2014 blocarea PD-1 permite celulelor T specifice tumorii s\u0103 recunoasc\u0103 \u0219i s\u0103 distrug\u0103 celulele canceroase.<\/li>\n<li><strong>Expresia PD-L1 \u00een tumoare prezice adesea r\u0103spunsul<\/strong> \u2014 tumorile cu colora\u021bie PD-L1 ridicat\u0103 (TPS \u2265 50%) r\u0103spund mai frecvent dec\u00e2t cele negative la PD-L1, \u00een special \u00een CBNPC. Unele indica\u021bii necesit\u0103 testare PD-L1 \u00eenainte de tratament.<\/li>\n<li><strong>Cancerele MSI-H \/ dMMR r\u0103spund independent de PD-L1<\/strong> \u2014 tumorile cu deficien\u021b\u0103 de reparare a nepotrivirilor sau instabilitate microsatelitar\u0103 r\u0103spund puternic la blocarea punctelor de control, indiferent de statutul PD-L1. Keytruda are o indica\u021bie tumor-agnostic\u0103 pentru cancerele MSI-H\/dMMR.<\/li>\n<li><strong>\u00cenc\u0103rc\u0103tura muta\u021bional\u0103 tumoral\u0103 (TMB)<\/strong> \u2014 tumorile cu TMB ridicat\u0103 genereaz\u0103 mai multe neoantigene pentru ca sistemul imun s\u0103 le recunoasc\u0103; unele indica\u021bii Keytruda folosesc TMB \u2265 10 mut\/Mb ca biomarker.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Utiliz\u0103ri \u0219i indica\u021bii<\/h2>\n<p>Keytruda este aprobat\u0103 de principalele autorit\u0103\u021bi de reglementare (FDA, EMA, MHRA, altele) pentru o gam\u0103 neobi\u0219nuit de larg\u0103 de cancere. Principalele indica\u021bii pentru adul\u021bi includ:<\/p>\n<ul>\n<li><strong>Melanom<\/strong> \u2014 avansat sau metastatic neresectabil; adjuvant pentru stadiile IIB\/IIC\/III dup\u0103 rezec\u021bie complet\u0103<\/li>\n<li><strong>Cancerul pulmonar non-microcelular (CBNPC)<\/strong> \u2014 monoterapie de prim\u0103 linie pentru CBNPC metastatic cu PD-L1 TPS \u2265 50%; combina\u021bie de prim\u0103 linie cu chimioterapia indiferent de PD-L1; monoterapie de linia a doua pentru PD-L1 \u2265 1%; terapie adjuvant\u0103 dup\u0103 rezec\u021bie<\/li>\n<li><strong>Carcinomul scuamos de cap \u0219i g\u00e2t (HNSCC)<\/strong> \u2014 primul r\u00e2nd metastatic \/ recurent (cu sau f\u0103r\u0103 chimioterapie)<\/li>\n<li><strong>Limfom Hodgkin clasic<\/strong> \u2014 recidivat sau refractar dup\u0103 chimioterapie cu agen\u021bi multipli<\/li>\n<li><strong>Carcinom urotelial<\/strong> \u2014 primul r\u00e2nd metastatic la pacien\u021bii neeligibili pentru cisplatin\u0103; al doilea r\u00e2nd dup\u0103 chimioterapia cu platin\u0103; cancer vezical non-muscular invaziv cu risc ridicat (nereactiv la BCG)<\/li>\n<li><strong>Cancere MSI-H \/ dMMR<\/strong> \u2014 indica\u021bie agnostic\u0103 de tumoare pentru orice tumoare solid\u0103 cu statut MSI-high sau deficien\u021b\u0103 de reparare a nepotrivirilor; deosebit de important \u00een cancerul colorectal, endometrial \u0219i gastric<\/li>\n<li><strong>Cancer gastric \u0219i de jonc\u021biune gastroesofagian\u0103<\/strong> \u2014 primul r\u00e2nd HER2+ (cu chimioterapie) \u0219i HER2- (cu chimioterapie)<\/li>\n<li><strong>Cancer esofagian<\/strong><\/li>\n<li><strong>Cancer cervical<\/strong> \u2014 primul r\u00e2nd PD-L1+ persistent, recurent sau metastatic (cu chimioterapie \u00b1 bevacizumab)<\/li>\n<li><strong>Carcinom hepatocelular (ficat)<\/strong><\/li>\n<li><strong>Carcinom celular renal<\/strong> \u2014 primul r\u00e2nd \u00een combina\u021bie cu axitinib sau lenvatinib<\/li>\n<li><strong>Cancer endometrial<\/strong> \u2014 pMMR (cu lenvatinib) \u0219i dMMR\/MSI-H (monoterapie)<\/li>\n<li><strong>Cancer de s\u00e2n triplu negativ (TNBC)<\/strong> \u2014 neoadjuvant \u00een stadiu precoce de risc ridicat (cu chimioterapie) \u0219i metastatic PD-L1+ (CPS \u2265 10)<\/li>\n<li><strong>Carcinom cutanat cu celule scuamoase<\/strong>, carcinom cu celule Merkel, limfom primar mediastinal cu celule mari B \u0219i mai multe indica\u021bii rare agnostice pentru tipul de tumoare<\/li>\n<\/ul>\n<p>Indica\u021bia \u0219i combina\u021bia corect\u0103 pentru Keytruda depind de tipul de tumoare, stadiu, statutul biomarkeri (PD-L1 TPS sau CPS, MSI\/dMMR, TMB, HER2) \u0219i terapia anterioar\u0103. <strong>Aceasta este o decizie a oncologului specialist dup\u0103 finalizarea evalu\u0103rii patologice \u0219i a biomarkeri.<\/strong><\/p>\n<h2 class=\"wp-block-heading\">Doza \u0219i administrare Keytruda<\/h2>\n<p>Doza standard pentru adul\u021bi:<\/p>\n<ul>\n<li><strong>200 mg perfuzie IV la fiecare 3 s\u0103pt\u0103m\u00e2ni<\/strong> (programul original) SAU<\/li>\n<li><strong>400 mg perfuzie intravenoas\u0103 la fiecare 6 s\u0103pt\u0103m\u00e2ni<\/strong> (dozare fix\u0103 Q6W \u2014 eficacitate echivalent\u0103 cu vizite mai pu\u021bin frecvente)<\/li>\n<li>Doza pediatric\u0103: 2 mg\/kg (maximum 200 mg) IV la fiecare 3 s\u0103pt\u0103m\u00e2ni<\/li>\n<li>Fiecare perfuzie se administreaz\u0103 \u00een <strong>30 de minute<\/strong> prin filtru \u00een linie de 0,2\u20135 \u00b5m<\/li>\n<\/ul>\n<h3 class=\"wp-block-heading\">Cum se administreaz\u0103 Keytruda<\/h3>\n<ol>\n<li><strong>Doar \u00een spital sau unitate de oncologie ambulatorie.<\/strong> Keytruda este administrat de personal medical calificat sub supravegherea unui oncolog specialist \u2014 nu se auto-administreaz\u0103 \u0219i nu este administrat \u00een comunitate.<\/li>\n<li><strong>Preg\u0103tire pre-infuzie<\/strong> la fiecare ciclu: hemogram\u0103 complet\u0103, panel metabolic complet (teste hepatice, func\u021bie renal\u0103), func\u021bie tiroidian\u0103 (TSH, T4 liber) la fiecare 6 s\u0103pt\u0103m\u00e2ni, glicemie. Screening simptomatic pentru evenimente adverse imunorelate noi.<\/li>\n<li><strong>Premedica\u021bia nu este de obicei necesar\u0103<\/strong> \u2014 pembrolizumab nu provoac\u0103 grea\u021b\u0103 tipic\u0103 chimioterapiei sau reac\u021bii de hipersensibilitate. Antiemeticele nu sunt necesare.<\/li>\n<li><strong>Preg\u0103tire flacon:<\/strong> dilua\u021bi pembrolizumab \u00een solu\u021bie fiziologic\u0103 sau dextroz\u0103 5% p\u00e2n\u0103 la o concentra\u021bie final\u0103 de 1\u201310 mg\/mL. Utiliza\u021bi \u00een termen de 6 ore de la preparare dac\u0103 este depozitat la temperatura camerei, sau 24 de ore dac\u0103 este refrigerat.<\/li>\n<li><strong>perfuzie intravenoas\u0103 de 30 de minute<\/strong> printr-un filtru \u00een linie de 0,2\u20135 \u00b5m. Nu se administreaz\u0103 prin injec\u021bie intravenoas\u0103 rapid\u0103 sau bolus.<\/li>\n<li><strong>Frecven\u021ba ciclurilor<\/strong> conform programului (Q3W sau Q6W). Continua\u021bi p\u00e2n\u0103 la progresia bolii, toxicitate intolerabil\u0103 sau finalizarea duratei planificate de tratament (de obicei 24 de luni \u00een setting adjuvant; p\u00e2n\u0103 la progresie \u00een setting metastatic).<\/li>\n<li><strong>Monitorizare obligatorie<\/strong> pentru evenimente adverse imunologice la fiecare vizit\u0103: piele (erup\u021bie cutanat\u0103, vitiligo, dermatit\u0103), GI (diaree, durere abdominal\u0103), respirator (tuse, dispnee), endocrin (oboseal\u0103, modific\u0103ri de greutate, palpita\u021bii din cauza tiroiditei sau hipofizitei), ficat (icter), rinichi (creatinin\u0103), neurologic (sl\u0103biciune, parestezii).<\/li>\n<li><strong>\u00centrerupere permanent\u0103<\/strong> pentru irAEs de grad 3\u20134 de pneumonit\u0103, hepatit\u0103, nefrit\u0103, dermatit\u0103, neurotoxicitate, miocardit\u0103; irAEs recurente de grad 2\u20133 din orice sistem; sau orice irAE de grad 4.<\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">Efecte Secundare ale Keytruda<\/h2>\n<p>Pembrolizumab are un profil de toxicitate fundamental diferit de chimioterapia citotoxic\u0103. Categoria dominant\u0103 de efecte secundare este <strong>evenimente adverse legate de sistemul imunitar (irAEs)<\/strong> \u2014 reac\u021bii autoimune cauzate de activitatea imun\u0103 necontrolat\u0103 \u00eempotriva \u021besuturilor normale.<\/p>\n<p><strong>Comune (non-irAE):<\/strong> oboseal\u0103, sc\u0103derea apetitului, grea\u021b\u0103 (u\u0219oar\u0103), constipa\u021bie, diaree, artralgie, prurit, erup\u021bie cutanat\u0103, cefalee u\u0219oar\u0103.<\/p>\n<p><strong>Evenimente adverse imunologice comune (irAEs):<\/strong><\/p>\n<ul>\n<li><strong>Hipotiroidism<\/strong> (10\u201315%) \u0219i hipertiroidism (4\u20136%) \u2014 din cauza tiroiditei autoimune. De obicei necesit\u0103 levotiroxin\u0103 pe via\u021b\u0103. Verifica\u021bi TSH la fiecare 6 s\u0103pt\u0103m\u00e2ni.<\/li>\n<li><strong>Reac\u021bii cutanate<\/strong> \u2014 erup\u021bie cutanat\u0103, prurit, vitiligo, erup\u021bie lichenoid\u0103. Severe \u00een 1\u20133%.<\/li>\n<li><strong>Diaree \/ colit\u0103<\/strong> \u2014 1\u20133% cazuri severe. Riscul de perfora\u021bie intestinal\u0103 dac\u0103 nu este tratat\u0103.<\/li>\n<li><strong>Pneumonit\u0103<\/strong> (~3% orice grad, &lt; 1% severe) \u2014 dispnee sau tuse nou\u0103 necesit\u0103 CT toracic urgent.<\/li>\n<li><strong>Hepatit\u0103<\/strong> (~1% severe) \u2014 cre\u0219tere a enzimelor hepatice.<\/li>\n<li><strong>Insuficien\u021b\u0103 adrenal\u0103, hipofizit\u0103<\/strong> \u2014 oboseal\u0103, hipotensiune, hiponatremie. Poate necesita \u00eenlocuire cu corticosteroizi pe via\u021b\u0103.<\/li>\n<li><strong>Diabet zaharat tip 1<\/strong> \u2014 cetoacidoz\u0103 de debut. De obicei ireversibil\u0103; necesit\u0103 insulin\u0103 pe via\u021b\u0103.<\/li>\n<li><strong>Nefrit\u0103<\/strong> \u2014 cre\u0219terea creatininemiei.<\/li>\n<\/ul>\n<p><strong>Efecte adverse imunologice mai pu\u021bin frecvente dar importante:<\/strong> miocardit\u0103 (rar\u0103 dar cu mortalitate ridicat\u0103), neuropatii periferice \u0219i craniene, sindrom Guillain-Barr\u00e9, miastenie gravis, encefalit\u0103, polimialgie, uveit\u0103, reac\u021bii cutanate severe (sindrom Stevens-Johnson, TEN), anemie hemolitic\u0103, citopenii.<\/p>\n<p><strong>Principiu cheie \u00een tratarea efectelor adverse imunologice:<\/strong> gradul 1 se gestioneaz\u0103 cu tratament de sus\u021binere + monitorizare; gradul 2 se suspend\u0103 tratamentul + se ini\u021biaz\u0103 corticosteroizi sistemici (prednizon 0,5\u20131 mg\/kg); gradele 3\u20134 se suspend\u0103 sau se \u00eentrerupe definitiv + corticosteroizi \u00een doze mari (1\u20132 mg\/kg) + evaluare de specialitate endocrinologic\u0103 \/ gastroenterologic\u0103 \/ pneumologic\u0103 \/ cardiologic\u0103 dup\u0103 caz. Majoritatea efectelor adverse imunologice se amelioraz\u0103 cu terapie corticoid\u0103 prompt\u0103. Endocrinopatiile (tiroidiene, suprarenale, diabet zaharat tip 1) sunt de obicei permanente \u0219i necesit\u0103 terapie hormonal\u0103 de substitu\u021bie pe via\u021b\u0103.<\/p>\n<h2 class=\"wp-block-heading\">Avertismente \u0219i precau\u021bii<\/h2>\n<ul>\n<li><strong>Efecte adverse imunologice:<\/strong> pot afecta orice sistem de organe, pot ap\u0103rea \u00een orice moment al tratamentului (inclusiv luni dup\u0103 \u00eentrerupere). Educarea pacientului \u0219i a \u00eengrijitorului asupra simptomelor este obligatorie. Pacien\u021bii trebuie s\u0103 solicite \u00eengrijire medical\u0103 \u00een aceea\u0219i zi pentru: diaree sever\u0103 (&gt; 4 scaune peste nivelul de baz\u0103), dispnee de debut, oboseal\u0103 sever\u0103 cu hipotensiune, icter, dureri abdominale severe, dureri toracice, sl\u0103biciune sau amor\u021beal\u0103, erup\u021bie cutanat\u0103 sever\u0103 sau cefalee de debut + modific\u0103ri vizuale.<\/li>\n<li><strong>Boal\u0103 autoimun\u0103 preexistent\u0103<\/strong> (de ex. boal\u0103 inflamatorie intestinal\u0103, lupus, artrit\u0103 reumatoid\u0103, psoriazis, scleroz\u0103 multipl\u0103, diabet zaharat tip 1): Keytruda poate agrava sever boala de baz\u0103. Decizie risc-beneficiu de c\u0103tre oncolog + specialistul relevant.<\/li>\n<li><strong>Pacien\u021bi cu transplant de organe solide sau celule stem:<\/strong> Keytruda poate precipita respingerea transplantului sau boala graft-versus-host. Este necesar\u0103 supraveghere specializat\u0103.<\/li>\n<li><strong>Sarcina:<\/strong> contraindica\u021bie \u2014 pembrolizumab trece prin placent\u0103 \u0219i poate perturba toleran\u021ba imun\u0103 fetal\u0103, duc\u00e2nd la mort fetal\u0103 sau complica\u021bii autoimune. Contraceptie fiabil\u0103 pe tot parcursul tratamentului + 4 luni dup\u0103 ultima doz\u0103.<\/li>\n<li><strong>Al\u0103ptarea:<\/strong> evita\u021bi \u2014 imunoglobulinele sunt excretate \u00een laptele matern. A\u0219tepta\u021bi 4 luni dup\u0103 ultima doz\u0103.<\/li>\n<li><strong>Vaccinuri cu virus viu:<\/strong> contraindicated.<\/li>\n<li><strong>Infec\u021bie activ\u0103:<\/strong> suspendare \u00een caz de infec\u021bie grav\u0103.<\/li>\n<li><strong>Insuficien\u021b\u0103 hepatic\u0103\/renal\u0103 sever\u0103:<\/strong> date limitate; evaluare de specialitate.<\/li>\n<li><strong>Depozitare \u00een lan\u021b frigorific:<\/strong> flacoanele trebuie p\u0103strate la frigider 2\u20138\u00b0C \u0219i nu \u00eenghe\u021bate. Dep\u0103\u0219irea lan\u021bului frigorific invalideaz\u0103 flaconul.<\/li>\n<li><strong>Cost \u0219i rambursare:<\/strong> Keytruda este unul dintre cele mai scumpe medicamente oncologice (~10.000\u201314.000 USD pe doz\u0103 la pre\u021bul produc\u0103torului). Programele de acces pentru pacien\u021bi, pembrolizumab biosimilar unde este disponibil \u0219i genericele din \u021b\u0103rile de origine difer\u0103 semnificativ ca pre\u021b.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Contraindica\u021bii<\/h2>\n<ul>\n<li>Hipersensibilitate cunoscut\u0103 la pembrolizumab sau la orice excipient din flacon<\/li>\n<li>Sarcin\u0103 sau planificare a sarcinii<\/li>\n<li>Al\u0103ptare<\/li>\n<li>Boal\u0103 autoimun\u0103 sever\u0103 preexistent\u0103 (relativ\u0103; evaluare de specialitate)<\/li>\n<li>Pacien\u021bi cu transplant de organ solid (relativ\u0103; evaluare de specialitate; risc de respingere a transplantului)<\/li>\n<li>Infec\u021bie activ\u0103 necontrolat\u0103<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;\">Combina\u021bi cu<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Efect<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Ce s\u0103 face\u021bi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Corticoizi sistemici (cronici, echivalent prednizon &gt; 10 mg\/zi)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Suprim\u0103 r\u0103spunsul imun pe care Keytruda \u00eencearc\u0103 s\u0103-l stimuleze \u2014 poate reduce eficacitatea<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Evita\u021bi corticosteroizii de baz\u0103 cronici, dac\u0103 este posibil. Tratamentele scurte pentru gestionarea efectelor adverse imunologice sau alte indica\u021bii sunt \u00eenc\u0103 potrivite.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Alte imunosupresoare (ciclosporin\u0103, micofenolat, azatioprin\u0103)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">La fel ca mai sus \u2014 pot reduce eficacitatea Keytruda<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Evaluare de c\u0103tre specialist.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Vaccinuri cu virus viu (MMR, febr\u0103 galben\u0103, BCG, polio oral, varicel\u0103)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Risc de infec\u021bie diseminat\u0103 din cauza virusului vaccinal viu<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Contraindicate \u00een timpul terapiei cu Keytruda \u0219i pentru c\u00e2teva luni dup\u0103 aceasta.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Vaccinuri inactivate (grip\u0103 anual\u0103, pneumococ, COVID-19, hepatit\u0103 B)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Sigure \u0219i recomandate<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Practic\u0103 standard.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Chimioterapie concomitent\u0103 (carboplatin\u0103\/paclitaxel, lenvatinib, axitinib, altele)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Combina\u021bie standard pentru multiple indica\u021bii \u2014 eficacitate aditiv\u0103<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Regim specializat specific.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Inhibitori CTLA-4 (ipilimumab)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Blocarea combinat\u0103 PD-1 + CTLA-4 \u00eembun\u0103t\u0103\u021be\u0219te r\u0103spunsul \u00een unele indica\u021bii dar cre\u0219te semnificativ riscul de irAE<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Terapie combinat\u0103 specializat\u0103 cu monitorizare intensiv\u0103.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Instruc\u021biuni de Depozitare<\/h2>\n<ul>\n<li>P\u0103stra\u021bi flacoanele nefolosite la <strong>2\u20138\u00b0C<\/strong> \u00een ambalajul original, protejat de lumin\u0103. <strong>NU congela\u021bi.<\/strong><\/li>\n<li>Nu agita\u021bi flaconul.<\/li>\n<li>Solu\u021bia de perfuzie diluat\u0103: stabil\u0103 p\u00e2n\u0103 la 24 de ore la refrigerare sau 6 ore la temperatura camerei; nu congela\u021bi.<\/li>\n<li>Defectarea lan\u021bului frigorific (peste 8\u00b0C pentru &gt; 24 de ore) invalideaz\u0103 flaconul \u2014 nu utiliza\u021bi.<\/li>\n<li>P\u0103stra\u021bi departe de copii \u0219i animale de companie.<\/li>\n<li>Returna\u021bi flacoanele nefolosite la o farmacie sau unitate de oncologie pentru eliminare corespunz\u0103toare.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Alternative conexe pe MedsBase<\/h2>\n<p>Alte medicamente oncologice disponibile \u00eempreun\u0103 cu acest produs:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/anaridex\/\"><strong>Anaridex (anastrozol 1 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/xtane\/\"><strong>Xtane (exemestan 25 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/fempro\/\"><strong>Fempro (letrozol 2.5 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/letroheal\/\"><strong>Letroheal (letrozol 2,5 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/tamilong\/\"><strong>Tamilong (tamoxifen 10 \/ 20 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/tamodex\/\"><strong>Tamodex (tamoxifen 10 \/ 20 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/tamoxilon\/\"><strong>Tamoxilon (tamoxifen 10 \/ 20 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/cytotam\/\"><strong>Cytotam (tamoxifen 10 \/ 20 mg)<\/strong><\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/medsbase.com\/ro\/anti-cancer-medication\/\">R\u0103sfoi\u021bi toate medicamentele anti-cancer \u2192<\/a><\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">Cum difer\u0103 Keytruda de chimioterapie?<\/h3>\n<p>Chimioterapia distruge direct celulele care se divid rapid (celulele canceroase, dar \u0219i m\u0103duva osoas\u0103, foliculii de p\u0103r, mucoasa gastrointestinal\u0103), produc\u00e2nd efectele secundare clasice de mielosupresie, alopecie, mucozit\u0103, grea\u021b\u0103. Keytruda <strong>activeaz\u0103 sistemul imunitar al pacientului pentru a recunoa\u0219te \u0219i distruge celulele canceroase<\/strong> \u2014 nu distruge direct celulele. Prin urmare, efectele secundare sunt fundamental diferite: dominate de <strong>evenimente adverse legate de sistemul imunitar (irAEs)<\/strong> \u2014 reac\u021bii autoimune \u00een orice sistem de organe. Majoritatea pacien\u021bilor care iau Keytruda nu experimenteaz\u0103 profilul de toxicitate tipic chimioterapiei, de\u0219i multe scheme terapeutice combin\u0103 Keytruda cu chimioterapia.<\/p>\n<h3 class=\"wp-block-heading\">Ce \u00eenseamn\u0103 testarea PD-L1 pentru tratamentul meu cu Keytruda?<\/h3>\n<p>PD-L1 este proteina de pe celulele canceroase pe care o blocheaz\u0103 mecanismul de ac\u021biune al Keytrudei. Expresia PD-L1 \u00een tumori se m\u0103soar\u0103 prin imunohistochimie pe biopsie \u0219i se raporteaz\u0103 ca <strong>TPS (Scorul Propor\u021biei Tumorale)<\/strong> sau <strong>CPS (Scorul Pozitiv Combinat)<\/strong>. O expresie mai mare a PD-L1 prezice \u00een general un r\u0103spuns mai bun la Keytruda, \u00een special \u00een cancerul pulmonar non-microcelular (TPS \u2265 50% \u2192 monoterapie de prim\u0103 linie; 1\u201349% \u2192 a doua linie sau cu chimioterapie). Pentru unele indica\u021bii (cancer pulmonar non-microcelular, gastric, cervical, TNBC), testarea PD-L1 este obligatorie \u00eenainte de tratament. Pentru altele (cancere MSI-H\/dMMR, melanom, limfom Hodgkin), Keytruda este utilizat\u0103 indiferent de statutul PD-L1.<\/p>\n<h3 class=\"wp-block-heading\">Ce sunt evenimentele adverse legate de imunitate (irAEs) \u0219i de ce sunt at\u00e2t de importante?<\/h3>\n<p>irAEs reprezint\u0103 categoria dominant\u0103 de efecte secundare ale Keytruda \u2014 reac\u021bii autoimune cauzate de sistemul imunitar necontrolat care atac\u0103 \u021besuturile normale. Pot afecta orice organ: piele, tractul gastrointestinal (colit\u0103), pl\u0103m\u00e2ni (pneumonit\u0103), ficat (hepatit\u0103), tiroid\u0103, hipofiz\u0103, glande suprarenale, pancreas (diabet de tip 1), rinichi, nervi periferici, inim\u0103 (miocardit\u0103 rar\u0103 cu mortalitate ridicat\u0103). Pot ap\u0103rea <strong>\u00een orice moment \u00een timpul tratamentului \u0219i chiar luni dup\u0103 ultima doz\u0103<\/strong>. Severitatea variaz\u0103 de la gradul 1 (u\u0219or) la gradul 4 (care pune via\u021ba \u00een pericol). <strong>Recunoa\u0219terea timpurie este esen\u021bial\u0103<\/strong> \u2014 majoritatea irAEs r\u0103spund bine la corticosteroizii sistemici dac\u0103 sunt tratate prompt. Pacien\u021bii ar trebui s\u0103 aib\u0103 un num\u0103r de contact de oncologie disponibil 24 de ore \u0219i s\u0103 fie educa\u021bi s\u0103 sune \u00een aceea\u0219i zi pentru diaree sever\u0103 nou\u0103, dispnee, icter, oboseal\u0103 sever\u0103, sl\u0103biciune, modific\u0103ri ale vederii sau dureri toracice.<\/p>\n<h3 class=\"wp-block-heading\">Va vindeca Keytruda cancerul meu?<\/h3>\n<p>Pentru unii pacien\u021bi \u00een anumite indica\u021bii, Keytruda produce r\u0103spunsuri durabile care pot apropia de o vindecare func\u021bional\u0103 \u2014 \u00een special \u00een melanomul avansat, cancerele MSI-H\/dMMR \u0219i limfomul Hodgkin, unde supravie\u021buirea la 5 ani este acum substan\u021bial\u0103. \u00cen NSCLC \u0219i alte indica\u021bii, Keytruda prelunge\u0219te semnificativ supravie\u021buirea la un subset de pacien\u021bi. <strong>R\u0103spunsul este foarte individual<\/strong> \u0219i depinde de tipul tumorii, expresia PD-L1, statutul MSI\/TMB, terapia anterioar\u0103, starea func\u021bional\u0103 \u0219i dac\u0103 Keytruda este utilizat\u0103 ca monoterapie sau \u00een combina\u021bie. Discuta\u021bi rezultatul a\u0219teptat specific tumorii dumneavoastr\u0103 cu oncologul dumneavoastr\u0103.<\/p>\n<h3 class=\"wp-block-heading\">C\u00e2nd voi observa efectul Keytruda?<\/h3>\n<p>R\u0103spunsul imagistic este de obicei m\u0103surabil pentru prima dat\u0103 la <strong>9\u201312 s\u0103pt\u0103m\u00e2ni<\/strong> (dup\u0103 3\u20134 cicluri). Unii pacien\u021bi prezint\u0103 <strong>pseudoprogresie<\/strong> \u2014 o aparent\u0103 cre\u0219tere ini\u021bial\u0103 la prima scanare cauzat\u0103 de infiltra\u021bia tumorii cu celule imune, urmat\u0103 de un r\u0103spuns autentic. Este necesar\u0103 evaluarea specialistului \u00eenainte de a declara e\u0219ecul tratamentului pe baza imaginilor precoce.<\/p>\n<h3 class=\"wp-block-heading\">Pot primi vaccinuri cu virus vii \u00een timpul tratamentului cu Keytruda?<\/h3>\n<p>Nu \u2014 vaccinurile cu virus vii (MMR, febr\u0103 galben\u0103, BCG, polio oral, varicel\u0103) sunt contraindicate \u00een timpul terapiei cu Keytruda \u0219i pentru cel pu\u021bin 6 luni dup\u0103 ultima doz\u0103. Vaccinurile inactivate (vaccinul anual \u00eempotriva gripei, pneumococic, COVID-19, hepatita B) nu sunt doar sigure, ci \u0219i recomandate \u2014 pacien\u021bii cu cancer au un risc mai mare de infec\u021bie \u0219i ar trebui vaccina\u021bi proactiv.<\/p>\n<h3 class=\"wp-block-heading\">Pot lua steroizi \u00een timpul tratamentului cu Keytruda?<\/h3>\n<p>Cursurile scurte sau pe termen scurt de steroizi pentru gestionarea efectelor adverse imuno-mediate sunt adecvate \u0219i necesare. <strong>Doze mari cronice de steroizi<\/strong> (prednizon &gt; 10 mg\/zi echivalent pentru perioade prelungite) la baz\u0103 pot suprima r\u0103spunsul imun pe care Keytruda \u00eencearc\u0103 s\u0103-l stimuleze \u2014 oncologii \u00eencearc\u0103 s\u0103 reduc\u0103 aceste doze \u00eenainte de a \u00eencepe Keytruda. Dac\u0103 ave\u021bi nevoie de steroizi pentru alt\u0103 afec\u021biune (astm, boal\u0103 autoimun\u0103, transplant), discuta\u021bi cu oncologul.<\/p>\n<h3 class=\"wp-block-heading\">Este Keytruda sigur \u00een timpul sarcinii?<\/h3>\n<p>Nu \u2014 este absolut contraindicated. Pembrolizumab trece prin placent\u0103 \u0219i ar putea perturba toleran\u021ba imun\u0103 fetal\u0103 cu consecin\u021be grave (mort fetal\u0103, boli autoimune fetale). Contraceptia fiabil\u0103 este obligatorie pe tot parcursul tratamentului \u0218I pentru cel pu\u021bin <strong>4 luni dup\u0103 ultima doz\u0103<\/strong>. Evita\u021bi al\u0103ptarea \u00een timpul tratamentului \u0219i pentru 4 luni dup\u0103 acesta.<\/p>\n<h3 class=\"wp-block-heading\">De ce este Keytruda at\u00e2t de scump?<\/h3>\n<p>Pembrolizumabul este unul dintre cele mai scumpe medicamente anticancer la nivel global \u2014 o singur\u0103 doz\u0103 de 200 mg la pre\u021bul produc\u0103torului poate costa 10.000\u201314.000 USD pe pie\u021bele cu venituri mari, \u00eenainte de reduceri. Motive: produc\u021bia complex\u0103 de anticorpi monoclonali, monopolul de patent al produc\u0103torului p\u00e2n\u0103 \u00een 2028, recuperarea costurilor mari de cercetare-dezvoltare, pre\u021buri premium. Programele de asisten\u021b\u0103 pentru pacien\u021bi (programul ACT al Merck \u00een SUA, programe caritabile \u00een multe \u021b\u0103ri), genericele disponibile \u00een \u021b\u0103rile de origine \u0219i apari\u021bia biosimilarului de pembrolizumab pe unele pie\u021be reduc semnificativ costul. Discuta\u021bi despre asisten\u021ba financiar\u0103 cu asistentul social oncologic sau farmacistul dumneavoastr\u0103.<\/p>\n<h3 class=\"wp-block-heading\">C\u00e2t timp trebuie s\u0103 iau Keytruda?<\/h3>\n<p>Depinde de indica\u021bie. <strong>Terapie adjuvant\u0103<\/strong> (dup\u0103 interven\u021bie chirurgical\u0103 cu inten\u021bie curativ\u0103 \u00een melanom, cancer pulmonar nemicrocelular etc.): de obicei 1 an (17 cicluri la fiecare 3 s\u0103pt\u0103m\u00e2ni sau 9 cicluri la fiecare 6 s\u0103pt\u0103m\u00e2ni). <strong>Boal\u0103 metastatic\u0103<\/strong>: p\u00e2n\u0103 la progresia bolii, toxicitate intolerabil\u0103 sau completarea a 2 ani de terapie la pacien\u021bii cu r\u0103spuns complet sus\u021binut. Studiile originale au limitat durata la 2 ani; durabilitatea r\u0103spunsului dup\u0103 oprirea tratamentului la 2 ani a fost \u00eencurajatoare \u00een melanom \u0219i cancer pulmonar nemicrocelular, mai pu\u021bin stabilit\u0103 \u00een alte indica\u021bii.<\/p>\n<p><!-- medsbase-why-order --><\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Fiecare lot este procurat de la un <strong>produc\u0103tor certificat WHO-GMP<\/strong>. Comenzile sunt expediate \u00een ambalaje simple, f\u0103r\u0103 marc\u0103, de la partenerii no\u0219tri de onorare \u0219i acoperite de <a href=\"\/ro\/medsbase-re-shipment-assurance-policy\/\">Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a>: dac\u0103 un colet nu ajunge \u00een 20 de zile lucr\u0103toare, trimitem gratuit o nou\u0103 comand\u0103, f\u0103r\u0103 \u00eentreb\u0103ri.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Medicamente Anticanceroase Asem\u0103n\u0103toare<\/h3>\n<p>Alte medicamente oncologice disponibile \u00eempreun\u0103 cu acest produs:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/votrient\/\">Votrient (pazopanib 200\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/imatib\/\">Imatib (imatinib 100\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/veenat\/\">Veenat (imatinib 100\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/tamilong\/\">Tamilong (tamoxifen 10\/20 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/xtane\/\">Xtane (exemestan 25 mg)<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Inhibitor al punctului de control imun PD-1<br \/>\n\u2705 15+ indica\u021bii oncologice (melanom, NSCLC, tumori MSI-H\/dMMR agnostice, HNSCC, Hodgkin, urotheliale, RCC, TNBC, endometriale \u0219i altele)<br \/>\n\u2705 Perfuzie intravenoas\u0103 200 mg la fiecare 3 s\u0103pt\u0103m\u00e2ni SAU 400 mg la fiecare 6 s\u0103pt\u0103m\u00e2ni<br \/>\n\u2705 Administrat exclusiv \u00een spital\/unitate de zi de oncologie<br \/>\n\u2705 Supraveghere obligatorie de c\u0103tre oncolog specialist<\/p>\n<p>Keytruda con\u021bine pembrolizumab 100 mg\/4 mL (Merck\/MSD). Un anticorp monoclonal umanizat care blocheaz\u0103 PD-1 pentru a elibera recunoa\u0219terea celulelor canceroase de c\u0103tre sistemul imun. Necesit\u0103 \u00eengrijire specializat\u0103 condus\u0103 de oncolog, stadializare ini\u021bial\u0103 \u0219i testare biomolecular\u0103 (PD-L1, MSI\/dMMR) \u00eenainte de ini\u021biere.<\/p>","protected":false},"featured_media":53354,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223],"product_tag":[],"class_list":{"0":"post-53353","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","10":"first","11":"instock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/53353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=53353"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/53354"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=53353"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=53353"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=53353"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=53353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}